Nutriband Inc. (NASDAQ: NTRB) has significantly advanced its intellectual property strategy by obtaining a new trademark registration and international patent protection for its proprietary AVERSA transdermal drug delivery system. The company’s recent achievements underscore its commitment to developing innovative pharmaceutical technologies with enhanced safety features.
In February, the U.S. Patent and Trademark Office granted Nutriband a trademark registration covering pharmaceutical and product research and development. Simultaneously, the company received a new patent in Macao for its AVERSA platform, bringing its total international patent protection to 46 countries.
The AVERSA platform is specifically designed to address critical challenges in pharmaceutical drug delivery, focusing on reducing potential abuse, unauthorized diversion, and accidental exposure to potent medications like fentanyl. By developing advanced abuse-deterrent technologies, Nutriband aims to target a substantial market opportunity estimated between $80 million and $200 million in the United States.
These intellectual property milestones represent a strategic approach to long-term market protection and demonstrate the company’s innovation in pharmaceutical delivery systems. The expanding patent portfolio provides Nutriband with a competitive advantage in developing safer, more controlled drug delivery mechanisms.
Additionally, the company has established a strategic sports partnership with Charlotte FC, which is expected to enhance brand visibility and community engagement. This partnership complements Nutriband’s ongoing efforts to raise awareness about responsible medication use and innovative pharmaceutical technologies.
This news story relied on a press release distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Nutriband Strengthens Intellectual Property Portfolio for Abuse-Deterrent Drug Delivery.